Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
Maggi P, De Socio GV, Menzaghi B, Molteni C, Squillace N, Taramasso L, Guastavigna M, Gamboni G, Madeddu G, Vichi F, Cascio A, Sarchi E, Pellicanò G, Martinelli CV, Celesia BM, Valsecchi L, Gulminetti R, Cenderello G, Parisini A, Calza L, Falasca K, Orofino G, Ricci E, Di Biagio A, Bonfanti P. Maggi P, et al. Among authors: gulminetti r. BMC Infect Dis. 2022 Sep 23;22(1):745. doi: 10.1186/s12879-022-07739-y. BMC Infect Dis. 2022. PMID: 36151508 Free PMC article.
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, De Socio GV, Martinelli C, Gulminetti R, Maggi P, Orofino G, Vichi F, Di Biagio A, Bonfanti P; CISAI Study Group. Taramasso L, et al. Among authors: gulminetti r. BMC Infect Dis. 2018 Jul 31;18(1):357. doi: 10.1186/s12879-018-3268-5. BMC Infect Dis. 2018. PMID: 30064371 Free PMC article.
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project.
Bagella P, Squillace N, Ricci E, Gulminetti R, De Socio GV, Taramasso L, Pellicanò G, Menzaghi B, Celesia BM, Dentone C, Orofino G, Bonfanti P, Madeddu G. Bagella P, et al. Among authors: gulminetti r. Infect Drug Resist. 2019 May 23;12:1385-1391. doi: 10.2147/IDR.S203813. eCollection 2019. Infect Drug Resist. 2019. PMID: 31213857 Free PMC article.
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
Taramasso L, De Vito A, Ricci ED, Orofino G, Squillace N, Menzaghi B, Molteni C, Gulminetti R, De Socio GV, Pellicanò GF, Sarchi E, Celesia BM, Calza L, Rusconi S, Valsecchi L, Martinelli CV, Cascio A, Maggi P, Vichi F, Angioni G, Guadagnino G, Cenderello G, Dentone C, Bandera A, Falasca K, Bonfanti P, Di Biagio A, Madeddu G; Behalf of the CISAI Study Group. Taramasso L, et al. Among authors: gulminetti r. AIDS Patient Care STDS. 2021 Sep;35(9):342-353. doi: 10.1089/apc.2021.0089. AIDS Patient Care STDS. 2021. PMID: 34524918
Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study.
Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, Calcagno A, Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group.. Muscatello A, et al. Among authors: gulminetti r. Pathog Immun. 2020 Feb 24;5(1):8-33. doi: 10.20411/pai.v5i1.341. eCollection 2020. Pathog Immun. 2020. PMID: 32258852 Free PMC article.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Castagna A, Rusconi S, Gulminetti R, Bonora S, Mazzola G, Quiros-Roldan ME, De Socio GV, Ladisa N, Carosella S, Cattelan A, Di Giambenedetto S, Mena M, Poli A, Galli L, Riva A; DAU Study Group. Castagna A, et al. Among authors: gulminetti r. AIDS. 2019 Jun 1;33(7):1256-1260. doi: 10.1097/QAD.0000000000002188. AIDS. 2019. PMID: 30870194 Free article.
Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy.
Bozzi G, Fabeni L, Abbate I, Berno G, Muscatello A, Taramasso L, Fabbiani M, Nozza S, Tambussi G, Rusconi S, Giacomelli A, Focà E, Pinnetti C, d'Ettorre G, Mussini C, Borghi V, Celesia BM, Madeddu G, Di Biagio A, Ripamonti D, Squillace N, Antinori A, Gori A, Capobianchi MR, Bandera A; INACTION study group. Bozzi G, et al. Sex Transm Infect. 2023 Feb;99(1):53-56. doi: 10.1136/sextrans-2021-055289. Epub 2022 Apr 20. Sex Transm Infect. 2023. PMID: 35443987 Free article.
81 results